These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 4555826)

  • 1. Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate.
    Kazamatsuri H; Chien C; Cole JO
    Arch Gen Psychiatry; 1972 Jul; 27(1):100-3. PubMed ID: 4555826
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.
    Kazamatsuri H; Chien C; Cole JO
    Arch Gen Psychiatry; 1972 Jul; 27(1):95-9. PubMed ID: 4555831
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.
    Kazamatsuri H; Chien CP; Cole JO
    Am J Psychiatry; 1973 Apr; 130(4):479-83. PubMed ID: 4570750
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic approaches to tardive dyskinesia. A review of the literature.
    Kazamatsuri H; Chien C; Cole JO
    Arch Gen Psychiatry; 1972 Oct; 27(4):491-9. PubMed ID: 4116201
    [No Abstract]   [Full Text] [Related]  

  • 5. Methylphenidate in tardive dyskinesia.
    Fann WE; Davis JM; Wilson IC
    Am J Psychiatry; 1973 Aug; 130(8):922-4. PubMed ID: 4577471
    [No Abstract]   [Full Text] [Related]  

  • 6. Thiopropazate hydrochloride in persistent dyskinesia.
    Singer K; Cheng MN
    Br Med J; 1971 Dec; 4(5787):626. PubMed ID: 5167074
    [No Abstract]   [Full Text] [Related]  

  • 7. Dexetimide (R 16470) in the control of neuroleptic-induced extrapyramidal side-effects. Its prophylactic value and duration of action.
    Huygens H; Vereecken JL; Tanghe A
    Psychiatr Neurol Neurochir; 1973; 76(4):251-9. PubMed ID: 4581374
    [No Abstract]   [Full Text] [Related]  

  • 8. Thiopropazate hydrochloride in persistent dyskinesia.
    Singer K; Cheng MN
    Br Med J; 1971 Oct; 4(5778):22-5. PubMed ID: 4938244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of tardive dyskinesia. 3. Clinical efficacy of a dopamine competing agent, methyldopa.
    Kazamatsuri H; Cole JO
    Arch Gen Psychiatry; 1972 Dec; 27(6):824-7. PubMed ID: 4637899
    [No Abstract]   [Full Text] [Related]  

  • 10. The neuroleptics. 10. Therapeutic problems.
    Barahona-Fernandes HJ; Cazzullo CL; Cocchi A; Denber HC; Freyhan FA; Klerman GL; Köknel O; Levine J; Saarma J; Sarteschi P; Vinar O; Wittenborn JR
    Mod Probl Pharmacopsychiatry; 1970; 5():148-56. PubMed ID: 4949818
    [No Abstract]   [Full Text] [Related]  

  • 11. Importance of dopamine metabolism for clinical effects and side effects of neuroleptics.
    Van Praag HM; Korf J
    Am J Psychiatry; 1976 Oct; 133(10):1171-7. PubMed ID: 970488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature.
    Crane GE
    Am J Psychiatry; 1968 Feb; 124(8):Suppl:40-8. PubMed ID: 4865731
    [No Abstract]   [Full Text] [Related]  

  • 13. Butaperazine (Repoise).
    Med Lett Drugs Ther; 1968 Nov; 10(22):89-90. PubMed ID: 4389275
    [No Abstract]   [Full Text] [Related]  

  • 14. The pharmacology of tardive dyskinesias.
    Klawans HL
    Am J Psychiatry; 1973 Jan; 130(1):82-6. PubMed ID: 4264755
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical observations of the treatment of tardive dyskinesia with haloperidol.
    Frangos E; Christodoulides H
    Acta Psychiatr Belg; 1975 Jan; 75(1):19-32. PubMed ID: 785948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea.
    McLellan DL; Chalmers RJ; Johnson RH
    Lancet; 1974 Jan; 1(7848):104-7. PubMed ID: 4130307
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of tardive dyskinesia with thiopropazate.
    Curran JP
    Am J Psychiatry; 1973 Aug; 130(8):925-7. PubMed ID: 4146097
    [No Abstract]   [Full Text] [Related]  

  • 18. Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesias.
    Rubovits R; Klawans HL
    Arch Gen Psychiatry; 1972 Oct; 27(4):502-7. PubMed ID: 5072718
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of choreatic disorders with thiopropazate (Dartal)].
    Neundörfer B; von Rad M
    Nervenarzt; 1971 Jun; 42(6):330-2. PubMed ID: 4253070
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention and management of tardive dyskinesia.
    Crane GE
    Am J Psychiatry; 1972 Oct; 129(4):466-7. PubMed ID: 5071149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.